December 19, 2024 10:13 AM EST
Deals

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Max Gelman

Senior Editor

Bris­tol My­ers Squibb is part­ner­ing with the orig­i­nal de­vel­op­er of Leqem­bi in a new Alzheimer’s dis­ease deal.

The large drug­mak­er

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Ab­b­Vie ex­ec­u­tives bask in Skyrizi, Rin­voq suc­cess­es as the drugs take up Hu­mi­ra's man­tle

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

Dai­ichi Sankyo taps new CEO, aims to build up ADC fran­chise

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times